Global Cancer Tumor Profiling Market
Global Cancer Tumor Profiling Market

Cancer Tumor Profiling Comprehensive Study by Type (Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Others (Melanoma, Colorectal, Bladder, Leukemia)), Application (Clinical, Screening, Research), Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Others), End Use (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications) Players and Region - Global Market Outlook to 2026

Cancer Tumor Profiling Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 233 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Cancer Tumor Profiling Market Overview:
Cancer tumour profiling is done to get genetic information regarding the tumour cells which offer useful insights and information regarding the disease. Cancer tumour profiling helps in the selection of suitable therapy for the treatment of cancer tumour. Cancer tumour profiling provides more precise and accurate information about the clinical outcomes of cancer. The technique plays an important role in the diagnosis of cancer at the molecular level. Cancer tumour profiling may increase the likelihood that a patient will benefit from cancer therapy. Some of the players profiled in the study are Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen N.V. (Netherlands), Neogenomics Laboratories Inc. (United States), HTG Molecular Diagnostics Inc. (United States), Perthera, Inc. (United States), Strand Genomics (India), Contextual Genomics (Canada), QIAGEN N.V. (Germany) and Boreal Genomics (United States).

On the basis of geography, the market of Cancer Tumor Profiling has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Next-Generation Sequencing (NGS) will boost the Cancer Tumor Profiling market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Personalized Medicine will boost the Cancer Tumor Profiling market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increase in the Demand for Next Generation Sequencing Techniques in Cancer Tumour Profiling
  • Rise in the Adoption of the Cancer Tumour Profiling Methods by Oncologists
  • Growing Need for Point-Of-Care Diagnostic Tests

Influencing Trend
  • Growing Utility of Biomarkers in Cancer Tumour Profiling
  • Rise in Number of Cancer Cases

Restraints
  • High Capital Investments
  • Lack of Skilled Professionals

Opportunities
  • Availability of Funding for Cancer Research
  • Increasing Demand for Personalized Medicine

Challenges
  • Targeting Cancer Stem Cells (CSCs) is Difficult
  • Problems Associated with Cancer Tumour Diagnosis


Key Market Developments:

March 08, 2019: QIAGEN N.V. and Tecan Group AG, a global leader in laboratory automation and liquid handling technology, announced a collaboration to improve the processing of QIAGENís QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the utilization of Tecanís Fluent Laboratory Automation.
March 11, 2019: NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announce availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations.

Target Audience:
Companies Offering Platforms for Cancer Tumour Diagnosis, Healthcare Industry, Research Institutes and Government Bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Cancer Tumor Profiling market on the basis of product [Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer and Others [Melanoma, Colorectal, Bladder, Leukemia]] , application [Clinical, Screening and Research], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Cancer Tumor Profiling market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Cancer Tumor Profiling industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Helomics Corp (United States), Oxford Gene Technology Ltd (United Kingdom), GenomeDx (Canada), Foundation Medicine Inc. (United States) and NanoString Technologies Inc. (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Cancer Tumor Profiling market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Kidney Cancer
  • Others [Melanoma, Colorectal, Bladder, Leukemia]
By Application
  • Clinical
  • Screening
  • Research
By Technology
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray
  • Others

By End Use
  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Research Applications

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Demand for Next Generation Sequencing Techniques in Cancer Tumour Profiling
      • 3.2.2. Rise in the Adoption of the Cancer Tumour Profiling Methods by Oncologists
      • 3.2.3. Growing Need for Point-Of-Care Diagnostic Tests
    • 3.3. Market Challenges
      • 3.3.1. Targeting Cancer Stem Cells (CSCs) is Difficult
      • 3.3.2. Problems Associated with Cancer Tumour Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Growing Utility of Biomarkers in Cancer Tumour Profiling
      • 3.4.2. Rise in Number of Cancer Cases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Tumor Profiling, by Type, Application, Technology, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cancer Tumor Profiling (Value)
      • 5.2.1. Global Cancer Tumor Profiling by: Type (Value)
        • 5.2.1.1. Breast Cancer
        • 5.2.1.2. Lung Cancer
        • 5.2.1.3. Prostate Cancer
        • 5.2.1.4. Thyroid Cancer
        • 5.2.1.5. Kidney Cancer
        • 5.2.1.6. Others [Melanoma, Colorectal, Bladder, Leukemia]
      • 5.2.2. Global Cancer Tumor Profiling by: Application (Value)
        • 5.2.2.1. Clinical
        • 5.2.2.2. Screening
        • 5.2.2.3. Research
      • 5.2.3. Global Cancer Tumor Profiling by: Technology (Value)
        • 5.2.3.1. Next-Generation Sequencing (NGS)
        • 5.2.3.2. Sanger Sequencing
        • 5.2.3.3. Immunohistochemistry (IHC)
        • 5.2.3.4. In Situ Hybridization (ISH)
        • 5.2.3.5. Microarray
        • 5.2.3.6. Others
      • 5.2.4. Global Cancer Tumor Profiling by: End Use (Value)
        • 5.2.4.1. Personalized Medicine
        • 5.2.4.2. Diagnostics
        • 5.2.4.3. Biomarker Discovery
        • 5.2.4.4. Prognostics
        • 5.2.4.5. Research Applications
      • 5.2.5. Global Cancer Tumor Profiling Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cancer Tumor Profiling: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Siemens Healthcare GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Qiagen N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Neogenomics Laboratories Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. HTG Molecular Diagnostics Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Perthera, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Strand Genomics (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Contextual Genomics (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. QIAGEN N.V. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boreal Genomics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Tumor Profiling Sale, by Type, Application, Technology, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cancer Tumor Profiling (Value)
      • 7.2.1. Global Cancer Tumor Profiling by: Type (Value)
        • 7.2.1.1. Breast Cancer
        • 7.2.1.2. Lung Cancer
        • 7.2.1.3. Prostate Cancer
        • 7.2.1.4. Thyroid Cancer
        • 7.2.1.5. Kidney Cancer
        • 7.2.1.6. Others [Melanoma, Colorectal, Bladder, Leukemia]
      • 7.2.2. Global Cancer Tumor Profiling by: Application (Value)
        • 7.2.2.1. Clinical
        • 7.2.2.2. Screening
        • 7.2.2.3. Research
      • 7.2.3. Global Cancer Tumor Profiling by: Technology (Value)
        • 7.2.3.1. Next-Generation Sequencing (NGS)
        • 7.2.3.2. Sanger Sequencing
        • 7.2.3.3. Immunohistochemistry (IHC)
        • 7.2.3.4. In Situ Hybridization (ISH)
        • 7.2.3.5. Microarray
        • 7.2.3.6. Others
      • 7.2.4. Global Cancer Tumor Profiling by: End Use (Value)
        • 7.2.4.1. Personalized Medicine
        • 7.2.4.2. Diagnostics
        • 7.2.4.3. Biomarker Discovery
        • 7.2.4.4. Prognostics
        • 7.2.4.5. Research Applications
      • 7.2.5. Global Cancer Tumor Profiling Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Tumor Profiling: by Type(USD Million)
  • Table 2. Cancer Tumor Profiling Breast Cancer , by Region USD Million (2015-2020)
  • Table 3. Cancer Tumor Profiling Lung Cancer , by Region USD Million (2015-2020)
  • Table 4. Cancer Tumor Profiling Prostate Cancer , by Region USD Million (2015-2020)
  • Table 5. Cancer Tumor Profiling Thyroid Cancer , by Region USD Million (2015-2020)
  • Table 6. Cancer Tumor Profiling Kidney Cancer , by Region USD Million (2015-2020)
  • Table 7. Cancer Tumor Profiling Others [Melanoma, Colorectal, Bladder, Leukemia] , by Region USD Million (2015-2020)
  • Table 8. Cancer Tumor Profiling: by Application(USD Million)
  • Table 9. Cancer Tumor Profiling Clinical , by Region USD Million (2015-2020)
  • Table 10. Cancer Tumor Profiling Screening , by Region USD Million (2015-2020)
  • Table 11. Cancer Tumor Profiling Research , by Region USD Million (2015-2020)
  • Table 12. Cancer Tumor Profiling: by Technology(USD Million)
  • Table 13. Cancer Tumor Profiling Next-Generation Sequencing (NGS) , by Region USD Million (2015-2020)
  • Table 14. Cancer Tumor Profiling Sanger Sequencing , by Region USD Million (2015-2020)
  • Table 15. Cancer Tumor Profiling Immunohistochemistry (IHC) , by Region USD Million (2015-2020)
  • Table 16. Cancer Tumor Profiling In Situ Hybridization (ISH) , by Region USD Million (2015-2020)
  • Table 17. Cancer Tumor Profiling Microarray , by Region USD Million (2015-2020)
  • Table 18. Cancer Tumor Profiling Others , by Region USD Million (2015-2020)
  • Table 19. Cancer Tumor Profiling: by End Use(USD Million)
  • Table 20. Cancer Tumor Profiling Personalized Medicine , by Region USD Million (2015-2020)
  • Table 21. Cancer Tumor Profiling Diagnostics , by Region USD Million (2015-2020)
  • Table 22. Cancer Tumor Profiling Biomarker Discovery , by Region USD Million (2015-2020)
  • Table 23. Cancer Tumor Profiling Prognostics , by Region USD Million (2015-2020)
  • Table 24. Cancer Tumor Profiling Research Applications , by Region USD Million (2015-2020)
  • Table 25. South America Cancer Tumor Profiling, by Country USD Million (2015-2020)
  • Table 26. South America Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 27. South America Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 28. South America Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 29. South America Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 30. Brazil Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 31. Brazil Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 32. Brazil Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 33. Brazil Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 34. Argentina Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 35. Argentina Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 36. Argentina Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 37. Argentina Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 38. Rest of South America Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 40. Rest of South America Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 41. Rest of South America Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 42. Asia Pacific Cancer Tumor Profiling, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 45. Asia Pacific Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 46. Asia Pacific Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 47. China Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 48. China Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 49. China Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 50. China Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 51. Japan Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 52. Japan Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 53. Japan Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 54. Japan Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 55. India Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 56. India Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 57. India Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 58. India Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 59. South Korea Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 60. South Korea Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 61. South Korea Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 62. South Korea Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 63. Taiwan Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 64. Taiwan Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 65. Taiwan Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 66. Taiwan Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 67. Australia Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 68. Australia Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 69. Australia Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 70. Australia Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 75. Europe Cancer Tumor Profiling, by Country USD Million (2015-2020)
  • Table 76. Europe Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 77. Europe Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 78. Europe Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 79. Europe Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 80. Germany Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 81. Germany Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 82. Germany Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 83. Germany Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 84. France Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 85. France Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 86. France Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 87. France Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 88. Italy Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 89. Italy Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 90. Italy Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 91. Italy Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 92. United Kingdom Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 93. United Kingdom Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 94. United Kingdom Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 95. United Kingdom Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 96. Netherlands Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 97. Netherlands Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 98. Netherlands Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 99. Netherlands Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 100. Rest of Europe Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 101. Rest of Europe Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 102. Rest of Europe Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 103. Rest of Europe Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 104. MEA Cancer Tumor Profiling, by Country USD Million (2015-2020)
  • Table 105. MEA Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 106. MEA Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 107. MEA Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 108. MEA Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 109. Middle East Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 110. Middle East Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 111. Middle East Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 112. Middle East Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 113. Africa Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 114. Africa Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 115. Africa Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 116. Africa Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 117. North America Cancer Tumor Profiling, by Country USD Million (2015-2020)
  • Table 118. North America Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 119. North America Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 120. North America Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 121. North America Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 122. United States Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 123. United States Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 124. United States Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 125. United States Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 126. Canada Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 127. Canada Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 128. Canada Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 129. Canada Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 130. Mexico Cancer Tumor Profiling, by Type USD Million (2015-2020)
  • Table 131. Mexico Cancer Tumor Profiling, by Application USD Million (2015-2020)
  • Table 132. Mexico Cancer Tumor Profiling, by Technology USD Million (2015-2020)
  • Table 133. Mexico Cancer Tumor Profiling, by End Use USD Million (2015-2020)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Cancer Tumor Profiling: by Type(USD Million)
  • Table 145. Cancer Tumor Profiling Breast Cancer , by Region USD Million (2021-2026)
  • Table 146. Cancer Tumor Profiling Lung Cancer , by Region USD Million (2021-2026)
  • Table 147. Cancer Tumor Profiling Prostate Cancer , by Region USD Million (2021-2026)
  • Table 148. Cancer Tumor Profiling Thyroid Cancer , by Region USD Million (2021-2026)
  • Table 149. Cancer Tumor Profiling Kidney Cancer , by Region USD Million (2021-2026)
  • Table 150. Cancer Tumor Profiling Others [Melanoma, Colorectal, Bladder, Leukemia] , by Region USD Million (2021-2026)
  • Table 151. Cancer Tumor Profiling: by Application(USD Million)
  • Table 152. Cancer Tumor Profiling Clinical , by Region USD Million (2021-2026)
  • Table 153. Cancer Tumor Profiling Screening , by Region USD Million (2021-2026)
  • Table 154. Cancer Tumor Profiling Research , by Region USD Million (2021-2026)
  • Table 155. Cancer Tumor Profiling: by Technology(USD Million)
  • Table 156. Cancer Tumor Profiling Next-Generation Sequencing (NGS) , by Region USD Million (2021-2026)
  • Table 157. Cancer Tumor Profiling Sanger Sequencing , by Region USD Million (2021-2026)
  • Table 158. Cancer Tumor Profiling Immunohistochemistry (IHC) , by Region USD Million (2021-2026)
  • Table 159. Cancer Tumor Profiling In Situ Hybridization (ISH) , by Region USD Million (2021-2026)
  • Table 160. Cancer Tumor Profiling Microarray , by Region USD Million (2021-2026)
  • Table 161. Cancer Tumor Profiling Others , by Region USD Million (2021-2026)
  • Table 162. Cancer Tumor Profiling: by End Use(USD Million)
  • Table 163. Cancer Tumor Profiling Personalized Medicine , by Region USD Million (2021-2026)
  • Table 164. Cancer Tumor Profiling Diagnostics , by Region USD Million (2021-2026)
  • Table 165. Cancer Tumor Profiling Biomarker Discovery , by Region USD Million (2021-2026)
  • Table 166. Cancer Tumor Profiling Prognostics , by Region USD Million (2021-2026)
  • Table 167. Cancer Tumor Profiling Research Applications , by Region USD Million (2021-2026)
  • Table 168. South America Cancer Tumor Profiling, by Country USD Million (2021-2026)
  • Table 169. South America Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 170. South America Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 171. South America Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 172. South America Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 173. Brazil Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 174. Brazil Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 175. Brazil Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 176. Brazil Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 177. Argentina Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 178. Argentina Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 179. Argentina Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 180. Argentina Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 181. Rest of South America Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 182. Rest of South America Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 183. Rest of South America Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 184. Rest of South America Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 185. Asia Pacific Cancer Tumor Profiling, by Country USD Million (2021-2026)
  • Table 186. Asia Pacific Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 187. Asia Pacific Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 188. Asia Pacific Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 189. Asia Pacific Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 190. China Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 191. China Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 192. China Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 193. China Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 194. Japan Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 195. Japan Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 196. Japan Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 197. Japan Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 198. India Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 199. India Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 200. India Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 201. India Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 202. South Korea Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 203. South Korea Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 204. South Korea Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 205. South Korea Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 206. Taiwan Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 207. Taiwan Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 208. Taiwan Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 209. Taiwan Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 210. Australia Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 211. Australia Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 212. Australia Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 213. Australia Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 217. Rest of Asia-Pacific Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 218. Europe Cancer Tumor Profiling, by Country USD Million (2021-2026)
  • Table 219. Europe Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 220. Europe Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 221. Europe Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 222. Europe Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 223. Germany Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 224. Germany Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 225. Germany Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 226. Germany Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 227. France Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 228. France Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 229. France Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 230. France Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 231. Italy Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 232. Italy Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 233. Italy Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 234. Italy Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 235. United Kingdom Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 236. United Kingdom Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 237. United Kingdom Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 238. United Kingdom Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 239. Netherlands Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 240. Netherlands Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 241. Netherlands Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 242. Netherlands Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 243. Rest of Europe Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 244. Rest of Europe Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 245. Rest of Europe Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 246. Rest of Europe Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 247. MEA Cancer Tumor Profiling, by Country USD Million (2021-2026)
  • Table 248. MEA Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 249. MEA Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 250. MEA Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 251. MEA Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 252. Middle East Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 253. Middle East Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 254. Middle East Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 255. Middle East Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 256. Africa Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 257. Africa Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 258. Africa Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 259. Africa Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 260. North America Cancer Tumor Profiling, by Country USD Million (2021-2026)
  • Table 261. North America Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 262. North America Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 263. North America Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 264. North America Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 265. United States Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 266. United States Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 267. United States Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 268. United States Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 269. Canada Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 270. Canada Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 271. Canada Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 272. Canada Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 273. Mexico Cancer Tumor Profiling, by Type USD Million (2021-2026)
  • Table 274. Mexico Cancer Tumor Profiling, by Application USD Million (2021-2026)
  • Table 275. Mexico Cancer Tumor Profiling, by Technology USD Million (2021-2026)
  • Table 276. Mexico Cancer Tumor Profiling, by End Use USD Million (2021-2026)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Tumor Profiling: by Type USD Million (2015-2020)
  • Figure 5. Global Cancer Tumor Profiling: by Application USD Million (2015-2020)
  • Figure 6. Global Cancer Tumor Profiling: by Technology USD Million (2015-2020)
  • Figure 7. Global Cancer Tumor Profiling: by End Use USD Million (2015-2020)
  • Figure 8. South America Cancer Tumor Profiling Share (%), by Country
  • Figure 9. Asia Pacific Cancer Tumor Profiling Share (%), by Country
  • Figure 10. Europe Cancer Tumor Profiling Share (%), by Country
  • Figure 11. MEA Cancer Tumor Profiling Share (%), by Country
  • Figure 12. North America Cancer Tumor Profiling Share (%), by Country
  • Figure 13. Global Cancer Tumor Profiling share by Players 2020 (%)
  • Figure 14. Global Cancer Tumor Profiling share by Players (Top 3) 2020(%)
  • Figure 15. Global Cancer Tumor Profiling share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2020
  • Figure 19. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 21. Qiagen N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Qiagen N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 23. Neogenomics Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Neogenomics Laboratories Inc. (United States) Revenue: by Geography 2020
  • Figure 25. HTG Molecular Diagnostics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. HTG Molecular Diagnostics Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Perthera, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Perthera, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Strand Genomics (India) Revenue, Net Income and Gross profit
  • Figure 30. Strand Genomics (India) Revenue: by Geography 2020
  • Figure 31. Contextual Genomics (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Contextual Genomics (Canada) Revenue: by Geography 2020
  • Figure 33. QIAGEN N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 34. QIAGEN N.V. (Germany) Revenue: by Geography 2020
  • Figure 35. Boreal Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Boreal Genomics (United States) Revenue: by Geography 2020
  • Figure 37. Global Cancer Tumor Profiling: by Type USD Million (2021-2026)
  • Figure 38. Global Cancer Tumor Profiling: by Application USD Million (2021-2026)
  • Figure 39. Global Cancer Tumor Profiling: by Technology USD Million (2021-2026)
  • Figure 40. Global Cancer Tumor Profiling: by End Use USD Million (2021-2026)
  • Figure 41. South America Cancer Tumor Profiling Share (%), by Country
  • Figure 42. Asia Pacific Cancer Tumor Profiling Share (%), by Country
  • Figure 43. Europe Cancer Tumor Profiling Share (%), by Country
  • Figure 44. MEA Cancer Tumor Profiling Share (%), by Country
  • Figure 45. North America Cancer Tumor Profiling Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Siemens Healthcare GmbH (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Qiagen N.V. (Netherlands)
  • Neogenomics Laboratories Inc. (United States)
  • HTG Molecular Diagnostics Inc. (United States)
  • Perthera, Inc. (United States)
  • Strand Genomics (India)
  • Contextual Genomics (Canada)
  • QIAGEN N.V. (Germany)
  • Boreal Genomics (United States)
Additional players considered in the study are as follows:
Helomics Corp (United States) , Oxford Gene Technology Ltd (United Kingdom) , GenomeDx (Canada) , Foundation Medicine Inc. (United States) , NanoString Technologies Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation